RecruitingNCT06398873

Effect of Dupilumab on Nasal Epithelial Barrier Function in Patients With CRSwNP

Effect of Dupilumab on Nasal Epithelial Barrier Function in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) - an Exploratory Pilot Study

Sponsor

Medical University of Vienna

Enrollment

80 participants

Start Date

Jun 6, 2024

Study Type

OBSERVATIONAL

Conditions

Chronic Rhinosinusitis With Nasal Polyps Chronic Rhinosinusitis Without Nasal Polyps

Summary

The investigators aim to investigate two major so far unresolved topics in CRSwNP research: (1) Thorough functional and molecular characterisation of barrier function in patients suffering from CRSsNP and CRSwNP and (2) effect of dupilumab treatment on barrier function in polyp patients. This will be achieved in patient-derived samples by employing measurement of barrier function in primary cell cultures in combination with a mass cytometry based imaging approach, transcriptomic analysis as well as cytokine and microbiome data of individual patients.

Eligibility

Min Age: 18 YearsMax Age: 99 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT] for people with chronic rhinosinusitis with nasal polyps and chronic rhinosinusitis without nasal polyps. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 99 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.